Opinion on  China Medical Technologies Inc ADS (CMED)     Sector: Healthcare  >  Industry: Medical Equipment & Supplies
CMED - Cooper

CMED

BUSINESS SUMMARY

China Medical Technologies, Inc. develops, manufactures, and markets medical devices for the treatment of solid cancers and benign tumors in the People's Republic of China. It offers In-vitro diagnostics systems, which include enhanced chemiluminescence immunoassay (ECLIA) system and fluorescent in situ hybridization (FISH) imaging analysis system and probes. The company's ECLIA system consists of ECLIA analyzer for detecting minute levels of light triggered by combining reagents with body fluid samples to produce diagnostic results; reagent kits, which are formulated to create various reactions with blood or other body fluid samples; and a data analysis system to analyze and organize the information produced form diagnostic results. It offers 62 types of reagent kits for use with the ECLIA analyzer for detecting and monitoring various types of diseases and disorders, including thyroid disorders, diabetes, hepatitis, and disorders related to reproduction and growth, SARS, Down syndrome, liver fibrosis, and various types of tumors. China Medical Technologies also offers FISH imaging analysis system and probes, which uses FISH technology for prenatal and postnatal diagnosis, and early detection and prognosis of various cancers. In addition, the company provides HIFU therapy system to treat liver, breast, and kidney tumors; solid tumors in the pelvic cavity or on bone; and tumors in the four limbs or superficial tissues. It sells its products through direct sales force and distributors. China Medical Technologies was founded in 1999 and is based in Beijing, the People's Republic of China.